Clinical experience of MEK inhibitors in cancer therapy

Biochim Biophys Acta. 2007 Aug;1773(8):1248-55. doi: 10.1016/j.bbamcr.2006.11.009. Epub 2006 Nov 16.

Abstract

Finding new therapies to assist in the treatment of cancer is a major challenge of clinical research. Small molecules that inhibit different molecular targets at the different levels of the MAPK pathway have been developed. Several MEK inhibitors have been examined in early-phase clinical trials and the current state of clinical results using these therapies is presented here.

Publication types

  • Review

MeSH terms

  • Clinical Trials as Topic
  • Drug Resistance, Neoplasm / genetics
  • Genes, ras
  • Humans
  • MAP Kinase Signaling System
  • Mitogen-Activated Protein Kinase Kinases / antagonists & inhibitors*
  • Mitogen-Activated Protein Kinase Kinases / genetics
  • Mutation
  • Neoplasms / drug therapy*
  • Neoplasms / enzymology*
  • Neoplasms / genetics
  • Protein Kinase Inhibitors / chemistry
  • Protein Kinase Inhibitors / therapeutic use*
  • Proto-Oncogene Proteins B-raf / genetics

Substances

  • Protein Kinase Inhibitors
  • BRAF protein, human
  • Proto-Oncogene Proteins B-raf
  • Mitogen-Activated Protein Kinase Kinases